Milmed Unico AB has been a proud member of Sweden Bio for several years, Sweden Bio is our national organization for Swedish Life Science companies. In every encounter or meeting new ideas, cooperation’s and knowledge are born and formed. Our CEO Thomas Lenz attended their 20th birthday-gala which turned out to be another world-class event.… Read More »Member of Sweden Bio
We are members of Pharmabiotic Research Institute and was specially invited to participate at this distinguished conference. With close to 110 companies representing big pharma, investors and (9 universities) much more this an event we don’t want to miss. The microbiome and its role in human health represents a paradigm shift in how medicines will… Read More »Milmed Unico AB’s CEO Thomas Lenz participates at Pharmabiotics 2022, Lyon
Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet. Swiss Nordic Bio carries 15 years of tradition, previously Swiss Scandinavian Bio-Business Seminar, and is organized by the Nordic countries in cooperation with Swiss partners. The conference has a broad focus within biotech… Read More »Milmed Unico AB’s CEO Thomas Lenz participates at Swiss Nordic Bio, Zürich
Trevor Archer 1*, Rose Mary Erixon 1,2, Thomas Lenz 1 and Rita Businaro 3 In March of 2022 Milmed Unico published a research article in Journal of Immunology and Allergy. In this article one can find interesting details regarding health benefits and much more from Milmed. Please read the full article here.
Starting in October of 2021 Dr. Anders Milton is taking over as chairman of Milmed Unico AB. The company is very satisfied with this recruitment as Dr. Milton has an experience touching into many of our future challenges. He has an impressive and extensive competence gathered from education and honorable assignments, please see below. We… Read More »Doctor Anders Milton becomes new chairman for Milmed Unico AB
Milmed Unico AB have filed a new patent application the 30th of June. The patent is for Treatment of inflammation. In vitro studies at Sapienza University have given significant results. In vivo studies will be performed and first study will focus on IBS ( Irritable Bowel Syndrome.